Small Molecules vs. Biologics: The “Same” Patent Fight—With Completely Different Rules
Drugmakers love to talk about “patent strategy” as if it were one playbook. But the moment you move from small molecules to biologics, the game changes—sometimes dra…
Biopharma vendors: the tender isn’t the deal—your timing is.
Drug patent cliffs don’t just reshape pipelines. They reshape procurement. And if you sell into EU markets—especially with tender strategy consulting—your competitive edge is less about pit…
Pharma doesn’t always “invent” new drugs. Sometimes it simply re-labels old molecules—and monetizes them like they’re new.
That’s the uncomfortable truth behind a growing playbook: take a mature drug, find a fresh indication, tweak the evidence, and—if…
Biopharma is entering a new kind of “cliff”—not just the loss of exclusivity, but the scramble to protect revenue when generics and authorized copies arrive faster than brand teams can repackage the story.
Here’s the agitation: most companies still tre…
Most pharma teams don’t lose patent value because they can’t innovate—they lose it because they pick the wrong patent to extend.
That sounds harsh, but it’s the reality behind “one-shot” patent strategy: when you’re trying to maximize the incremental v…
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a strategy. In practice, it’s a discipline: a way of reading formulation patent claims like a map, then…
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”—and what does it mean for your pipeline, your pricing power, and your next 5–10 years of cash flow?
That’s the subtext behind a t…
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose in Eurasia because they didn’t know the science. They lose because they didn’t know the rules of time.
That’s the real takeaway from Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know—and it’s a war…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Get new actionable insights and updates from BiotechBlog
